Turning Tides, a DTC campaign from Biogen and Supernus, uses storm-at-sea imagery and a streaming-first media plan to connect with new parents and spotlight the first oral treatment for postpartum ...

Biogen’s salanersen is now heading into three Phase III trials in SMA.

More early-stage data show the drug, called salanersen, appeared to have positive effects on neurodegeneration and motor function in patients previously treated with Novartis' Zolgensma.

New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due ...

CEO Christopher Viehbacher told investors at TD Cowen’s 46th Annual Healthcare Conference that the company is focused on building what he described as “a whole new era of growth” through a broadened ...

Cambridge, Massachusetts-based Biogen Inc. (BIIB) is a biotechnology company that discovers, develops, and delivers innovative therapies for serious neurological and neurodegenerative diseases. It is ...

Biogen (NASDAQ:BIIB) outlined its growing “West Coast Hub” and development plans for felzartamab, an anti-CD38 antibody being studied across multiple kidney-related immunology indications, during a ...

One of the healthier stocks on the market Friday was veteran biotech Biogen (NASDAQ: BIIB). The company unveiled its final set of fundamentals for 2025, and it crushed analyst estimates for both ...

The science behind rare disease treatments is advancing at an unprecedented pace. Biogen is sharpening its long-term strategy ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 9:10 AM ESTCompany ParticipantsChristopher Viehbacher - President, CEO ...

Biogen announced it will buy Human Immunology Biosciences (HI-Bio) in a deal worth up to $1.8 billion Wednesday morning. Per terms of the transaction, Biogen will make an upfront payment of $1.15 ...

Patient Capital Management, a value investing firm, released its “Patient Opportunity Equity Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, ...